Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Anlotinib in PD-1/PD-L1 Resistant Gastric or Colorectal Cancer
NCT04777162Phase 2Unknown
- Sponsor
- Peking University
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in gastric cancer (GC), colorectal cancer (CRC), sponsored by Peking University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04777162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777162.